Biocon Biologics (BB), a subsidiary of Biocon said it will offer a 15 per cent stake to the Serum Institute of Life Sciences (SILS), at a post-money valuation of US $ 4.9 billion. SILS is a subsidiary of Serum Institute of India.

BB will get committed access to 100 million doses of vaccines per annum for 15 years, primarily from  SILS’s upcoming vaccine facility in Pune with commercialisation rights of the SILS vaccine portfolio (including Covid-19 vaccines) for global markets.

According to the terms of the agreement, Biocon Biologics will generate a committed revenue stream and related margins, commencing H2, FY23. Adar Poonawalla will have a Board seat in Biocon Biologics.

In addition to vaccines, the strategic alliance will also develop antibodies targeting several infectious diseases like Dengue, HIV, etc. The two companies will enter Service Level Agreements (SLAs) for manufacturing and distribution of the vaccines and antibodies.

Vaccines are a complementary business fit to Biocon Biologics and provide a new dimension to its effort in improving global healthcare. Most recently, Biocon Biologics announced a manufacturing and commercialisation partnership in select emerging markets with Boston based Adagio Therapeutics Inc. for ADG20, a novel Covid-19 antibody therapy. These collaborations support Biocon Biologics’ intent of straddling on both infectious and non-communicable diseases in its quest to impact global health.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics, said: “This alliance will complement the strengths and resources of the two leading players in vaccines and biologics. Our shared vision of building large scale businesses having global impact makes it a unique and synergistic value creation opportunity.”

Adar Poonawalla, CEO, Serum Institute of India, commented: “We look forward to complementing each other’s capabilities and capacities in vaccines and biologics, to address inequitable access both in emerging and developed markets for life-saving vaccines and biologics.”

Biocon Biologics will also establish, at its cost, a vaccine R&D division to support the strategic alliance in developing both vaccines and biologics for communicable diseases. Additionally, wherever possible, it will make available its cell culture and sterile fill and finish capacities, for vaccine production under the strategic alliance.

Both companies believe that this is an alliance that can make a significant impact on global healthcare through vaccines and biologics.